Fig. 6: Growth factor-mediated resistance experiments.
From: Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
a Effect on LU65 proliferation IC50s with EGF treatment for dual inhibitor 8, inactive state-selective inhibitor divarasib, active state-selective inhibitor RMC-6291, and panRAS inhibitor RMC-6236. Data are from two independent experiments and are presented as mean ± SD. b Effect on H1792 proliferation IC50s with HGF treatment for the same collection of compounds. Data are from two independent experiments and are presented as mean ± SD. c Top: Effect on H1373 proliferation IC50s with HGF treatment for 8, divarasib, RMC-6291 and RMC-6236. Bottom: Attenuation of growth factor-mediated resistance using an H- and NRAS double knockout isogenic cell line. Data are from two independent experiments and are presented as mean ± SD. Source data are provided as a Source Data file.
